Capeserod

Capeserod (also spelled Capesared) is an experimental drug compound that was under development by GlaxoSmithKline (GSK). It is classified as a selective 5-HT4 receptor partial agonist.

Mechanism of Action

Capeserod operates by selectively binding to and partially activating serotonin 5-HT4 receptors. These receptors are widely distributed throughout the gastrointestinal (GI) tract, as well as in other systems including the central nervous system and the heart. In the GI tract, activation of 5-HT4 receptors stimulates the release of various neurotransmitters, predominantly acetylcholine, from enteric neurons. This action enhances propulsive motility in the colon, which in turn facilitates the movement of intestinal contents and promotes bowel movements.

Therapeutic Potential

Given its prokinetic properties on the gastrointestinal system, Capeserod was investigated for its potential application in the treatment of several GI motility disorders. Its primary intended therapeutic uses included:

• Chronic Constipation: Aimed at alleviating infrequent or difficult bowel movements.
• Irritable Bowel Syndrome with Constipation (IBS-C): A functional GI disorder characterized by abdominal pain, bloating, and constipation.

Development Status

Capeserod advanced through the initial stages of clinical development, reaching Phase II clinical trials. However, its development was ultimately discontinued by GlaxoSmithKline. The reasons for the cessation of drug development are typically complex and can include a lack of demonstrated superior efficacy compared to existing treatments, emerging safety concerns during trials, or commercial viability considerations. While specific detailed reasons for Capeserod's discontinuation have not been broadly disclosed, other drugs within the 5-HT4 agonist class have faced challenges related to potential cardiovascular side effects (such as QT prolongation), which can be a factor in their development pathways.